These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36193074)

  • 1.
    Chen Z; Cui S; Dai Y; Lu C; Zhang H; Zhao W; Yan H; Zhang Y
    Oxid Med Cell Longev; 2022; 2022():7595230. PubMed ID: 36193074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
    Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
    Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
    Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
    J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.
    Xu J; Liu F; Li Y; Shen L
    Cell Mol Neurobiol; 2022 Apr; 42(3):709-722. PubMed ID: 32894375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TTC7B is a new prognostic biomarker in head and neck squamous cell carcinoma linked to immune infiltration and ferroptosis.
    He R; Zhang X; Wu Y; Weng Z; Li L
    Cancer Med; 2023 Dec; 12(24):22354-22369. PubMed ID: 37990988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCAMP4 is a novel prognostic marker and correlated with the tumor progression and immune infiltration in glioma.
    Ge X; Wang Z; Jiang R; Ren S; Wang W; Wu B; Zhang Y; Liu Q
    Int J Biochem Cell Biol; 2021 Oct; 139():106054. PubMed ID: 34390854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
    Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
    Zhou K; Jiang T; Liu Y; Zhao Z; Huang L; Li G
    BMC Neurol; 2021 Nov; 21(1):438. PubMed ID: 34753441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
    Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
    Li J; Zhang Y; Qu Z; Ding R; Yin X
    Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and Prognostic Role of PANK1 in Glioma.
    Zhao Z; Xu X; Ma S; Li L
    Comb Chem High Throughput Screen; 2024; 27(5):715-724. PubMed ID: 37138430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.
    Wang D; Sun H; Li X; Wang G; Yan G; Ren H; Hou B
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N6-Methylandenosine-Related Gene
    Jiang X; Shi Y; Chen X; Xu H; Huang X; Li L; Pu J
    Front Mol Biosci; 2022; 9():773662. PubMed ID: 35309512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
    Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
    World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.